Logo image
Inflammatory Bowel Disease Following Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease
Journal article   Peer reviewed

Inflammatory Bowel Disease Following Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease

Emily Rowland, Akshay Sharma, Samantha Paglinco, Ross M Maltz, Jeffrey E Deyo, Kiran Joglekar, John Brannon Alberty, Courtney Fitzhugh and Hemalatha G Rangarajan
Pediatric blood & cancer, v 73(1), e32121
Jan 2026
PMID: 41116703

Abstract

Anemia, Sickle Cell - complications Anemia, Sickle Cell - therapy Graft vs Host Disease - etiology Graft vs Host Disease - prevention & control Hematopoietic Stem Cell Transplantation - adverse effects Humans Inflammatory Bowel Diseases - etiology Inflammatory Bowel Diseases - pathology Transplantation, Homologous
Although graft-versus-host disease (GvHD) is an important cause of gastrointestinal (GI) complications after allogeneic hematopoietic stem cell transplantation (HCT), the non-specific symptoms make diagnosis challenging. We described three patients with sickle cell disease who developed inflammatory bowel disease (IBD) like manifestations 4-18 months post-HCT. All patients received peripheral blood stem cell grafts and sirolimus for GvHD prophylaxis. All had chronic diarrhea, and biopsies showed extensive colonic ulceration, non-necrotizing granulomas, with minimal histologic evidence of GvHD. Symptoms resolved promptly with IBD-directed therapy. Our report highlights the importance of considering alternative rare etiologies for GI complications such as IBD after HCT.

Metrics

2 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Hematology
Oncology
Pediatrics
Logo image